It has been confirmed in animal models that the expression of programmed death ligand 2 (PD-L2) in tumor cells may inhibit antitumor immunity and may be involved in the resistance to monoanti-PD-L1 therapy (115). The gene discussed is CD274; the disease is neoplasm.